IL315704A - Anti-par2 antibodies - Google Patents

Anti-par2 antibodies

Info

Publication number
IL315704A
IL315704A IL315704A IL31570424A IL315704A IL 315704 A IL315704 A IL 315704A IL 315704 A IL315704 A IL 315704A IL 31570424 A IL31570424 A IL 31570424A IL 315704 A IL315704 A IL 315704A
Authority
IL
Israel
Prior art keywords
amino acid
seq
acid sequence
antibody
par2
Prior art date
Application number
IL315704A
Other languages
English (en)
Hebrew (he)
Inventor
Catherine Hutchings
Greg Osborne
Oliver Schlenker
Krzysztof Okrasa
Andrei Zhukov
Annika Schmid
Alexandra Kraus
Doreth?E R?Hle
Original Assignee
Nxera Pharma Uk Ltd
Catherine Hutchings
Greg Osborne
Oliver Schlenker
Krzysztof Okrasa
Andrei Zhukov
Annika Schmid
Alexandra Kraus
Doreth?E R?Hle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma Uk Ltd, Catherine Hutchings, Greg Osborne, Oliver Schlenker, Krzysztof Okrasa, Andrei Zhukov, Annika Schmid, Alexandra Kraus, Doreth?E R?Hle filed Critical Nxera Pharma Uk Ltd
Publication of IL315704A publication Critical patent/IL315704A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315704A 2022-03-24 2023-03-24 Anti-par2 antibodies IL315704A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2204159.4A GB202204159D0 (en) 2022-03-24 2022-03-24 Antibodies
PCT/GB2023/050760 WO2023180767A1 (en) 2022-03-24 2023-03-24 Anti-par2 antibodies

Publications (1)

Publication Number Publication Date
IL315704A true IL315704A (en) 2024-11-01

Family

ID=81449405

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315704A IL315704A (en) 2022-03-24 2023-03-24 Anti-par2 antibodies

Country Status (10)

Country Link
US (1) US20250313621A1 (https=)
EP (1) EP4499694A1 (https=)
JP (1) JP2025510815A (https=)
KR (1) KR20240161970A (https=)
CN (1) CN119137152A (https=)
AU (1) AU2023238937A1 (https=)
CA (1) CA3246035A1 (https=)
GB (1) GB202204159D0 (https=)
IL (1) IL315704A (https=)
WO (1) WO2023180767A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024255639A1 (en) * 2023-04-14 2025-10-02 Triveni Bio, Inc. Dual inhibitor trypsin antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MX2019010802A (es) 2017-03-16 2019-10-30 Medimmune Ltd Anticuerpos anti-par2 y usos de los mismos.
SMT202500106T1 (it) * 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso

Also Published As

Publication number Publication date
WO2023180767A1 (en) 2023-09-28
CA3246035A1 (en) 2023-09-28
CN119137152A (zh) 2024-12-13
JP2025510815A (ja) 2025-04-15
US20250313621A1 (en) 2025-10-09
GB202204159D0 (en) 2022-05-11
KR20240161970A (ko) 2024-11-13
AU2023238937A1 (en) 2024-10-31
EP4499694A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
TWI528974B (zh) 用於增加肌肉生長之組合物及方法
US10858446B2 (en) Anti-PCSK9 antibodies and uses thereof
JP2022137092A (ja) 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
JP7064666B2 (ja) ＦｃγＲＩＩＡに特異的な結合分子及びその使用
US11459389B2 (en) Monoclonal antibodies that bind human CD161
US20220340673A1 (en) Antibody targeting bcma, bispecific antibody, and use thereof
CN117567621A (zh) 抗lag-3抗体及组合物
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
KR102562418B1 (ko) 항-테나신 c 항체 및 이의 용도
TW202302634A (zh) 用於治療不正常子宮出血之IL-11或IL-11Ra抑制劑
JP7840312B2 (ja) 多重特異性結合性作用剤およびその使用
JP2024505674A (ja) 抗ｉｌ１ｒａｐ抗体
US20250313621A1 (en) Anti-par2 antibodies
TW202304975A (zh) 新穎抗sema3a抗體及其用途
JP2022540859A (ja) 新規ｂｓｓｌ抗体
JP2025503707A (ja) ガレクチン－１０抗体
WO2021043203A1 (en) Anti-cxcr2 antibodies and uses thereof
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도
TW202600594A (zh) 結合構築體(一)
WO2023064435A2 (en) Compositions and methods relating to sars-cov-2 neutralizing antibodies
HK40099698A (zh) 抗sema3a抗体及其用途